Norway Anticoagulants Market Size & Outlook, 2023-2030

The anticoagulants market in Norway is expected to reach a projected revenue of US$ 531.2 million by 2030. A compound annual growth rate of 8.5% is expected of Norway anticoagulants market from 2024 to 2030.
Revenue, 2023 (US$M)
$299.9
Forecast, 2030 (US$M)
$531.2
CAGR, 2024 - 2030
8.5%
Report Coverage
Norway

Norway anticoagulants market highlights

  • The Norway anticoagulants market generated a revenue of USD 299.9 million in 2023 and is expected to reach USD 531.2 million by 2030.
  • The Norway market is expected to grow at a CAGR of 8.5% from 2024 to 2030.
  • In terms of segment, novel oral anticoagulants (noacs) was the largest revenue generating drug category in 2023.
  • Heparin and Low Molecular Weight Heparin (LMWH) is the most lucrative drug category segment registering the fastest growth during the forecast period.


Anticoagulants market data book summary

Market revenue in 2023USD 299.9 million
Market revenue in 2030USD 531.2 million
Growth rate8.5% (CAGR from 2023 to 2030)
Largest segmentNovel oral anticoagulants (noacs)
Fastest growing segmentHeparin and Low Molecular Weight Heparin (LMWH)
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationNovel Oral Anticoagulants (NOACs), Vitamin K Antagonist, Direct Thrombin Inhibitors, Heparin and Low Molecular Weight Heparin (LMWH)
Key market players worldwideAspen Group Inc, Pfizer Inc, Bristol-Myers Squibb Co, GSK PLC, Sanofi SA, Bayer AG, Boehringer Ingelheim, Daiichi Sankyo Co Ltd, Johnson & Johnson, Eisai Co Ltd


Other key industry trends

  • In terms of revenue, Norway accounted for 0.9% of the global anticoagulants market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany anticoagulants market is projected to lead the regional market in terms of revenue in 2030.
  • Denmark is the fastest growing regional market in Europe and is projected to reach USD 330.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Anticoagulants Market Companies

Name Profile # Employees HQ Website

Norway anticoagulants market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anticoagulants market will help companies and investors design strategic landscapes.


Novel oral anticoagulants (noacs) was the largest segment with a revenue share of 57.25% in 2023. Horizon Databook has segmented the Norway anticoagulants market based on novel oral anticoagulants (noacs), vitamin k antagonist, direct thrombin inhibitors, heparin and low molecular weight heparin (lmwh) covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Norway anticoagulants market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Norway anticoagulants market databook

  • Our clientele includes a mix of anticoagulants market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Norway anticoagulants market , including forecasts for subscribers. This country databook contains high-level insights into Norway anticoagulants market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Norway anticoagulants market size, by drug category, 2018-2030 (US$M)

Norway Anticoagulants Market Outlook Share, 2023 & 2030 (US$M)

Norway anticoagulants market size, by drug category, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more